Summit Therapeutics (SMMT) Accumulated Expenses (2019 - 2026)

Summit Therapeutics (SMMT) has reported Accumulated Expenses for 8 consecutive years, with $65.1 million the latest figure, recorded in Q2 2026.

• Quarterly Accumulated Expenses rose 148.8% year-over-year to $65.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $65.1 million (up 148.8% YoY) and the FY2025 annual result came in at $32.1 million, up 64.16% from the prior year.
• Accumulated Expenses climbed to $65.1 million in Q2 2026 per SMMT's latest filing, from $44.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for SMMT reached as high as $65.1 million in Q2 2026 and fell as low as $3.7 million in Q3 2023.
• A 5-year average of $18.7 million and a median of $12.4 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses sank 67.2% — and 2024, when it jumped 405.67%.
• Year by year, Accumulated Expenses stood at $10.7 million in 2022, then fell by 17.64% to $8.8 million in 2023, then jumped by 122.63% to $19.6 million in 2024, then jumped by 64.16% to $32.1 million in 2025, then surged by 102.66% to $65.1 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $65.1 million, $44.3 million, and $32.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.